Cost-Effectiveness of the New Combination Trifluridine/Tipiracil Plus Bevacizumab for the Third-Line Treatment for Metastatic Colorectal Cancer in Italy

Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer

(2023) Gerald W. Prager et al.   NEW ENGLAND JOURNAL OF MEDICINE

Financial toxicity and cancer treatments: Help from biosimilars – The explanatory case of bevacizumab

(2020) Jacopo Giuliani et al.   EUROPEAN JOURNAL OF CANCER

Which grade is of clinical benefit in the randomised controlled trials? The example of 54th American Society of Clinical Oncology annual meeting, 2018

(2018) Jacopo Giuliani et al.   EUROPEAN JOURNAL OF CANCER

Generalizability of findings from randomized controlled trials is limited in the leading general medical journals

(2018) Antti Malmivaara   JOURNAL OF CLINICAL EPIDEMIOLOGY

The Pharmacological Costs of First-Line Therapies in Unselected Patients With Advanced Colorectal Cancer: A Review of Published Phase III Trials

(2016) Jacopo Giuliani et al.   Clinical Colorectal Cancer

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)

(2015) N. I. Cherny et al.   ANNALS OF ONCOLOGY

Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

(2015) Robert J. Mayer et al.   NEW ENGLAND JOURNAL OF MEDICINE